PF 4518600

Drug Profile

PF 4518600

Alternative Names: PF-04518600; PF-8600

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer M. D. Anderson Cancer Center; National Cancer Institute (USA); Pfizer; University of Southern California
  • Class Antibodies; Antineoplastics
  • Mechanism of Action OX40 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Renal cell carcinoma
  • Phase I/II Solid tumours

Most Recent Events

  • 02 Aug 2017 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease) in USA (IV) (NCT03217747)
  • 19 Jul 2017 Phase-II clinical trials in Renal cell carcinoma (Combination therapy, Metastatic disease, Second line or greater) in USA (IV) (NCT03092856)
  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top